Recombinant human G-CSF with a 3.5 hour half-life requiring daily subcutaneous or intravenous administration in the management of neutropenia.

Rapidly cleared by the kidneys

Dose is 5mcg/kg IV or sc daily.

Mild to moderate bone pain is most common reported adverse event.

Bone pain with colony stimulating factors for white blood clls is most common during the first cycle of treatment.

Used to decrease the incidence of febrile neutropenia in patients with malignancies who are receiving myelosuppressive therapy.

Brand name Neupogen.

Pegylated formulation Neulasta.

Leave a Reply

Your email address will not be published. Required fields are marked *